Glenmark Readying Xolair Biosimilar Challenge

Glenmark has received US FDA clearance of an IND to start clinical studies with a proposed biosimilar version of Xolair. The Indian company appears confident of addressing any price-related challenges although the targeted launch is still some years away.

The US FDA has approved Glenmark Pharmaceuticals Ltd.’s Investigational New Drug (IND) application to initiate a first-in-human study of GBR 310, the firm’s proposed biosimilar version of Roche/Novartis AG's Xolair (omalizumab); the study will assess the biosimilar’s pharmacokinetics in comparison to Xolair in healthy adult volunteers between 18 and 65 years of age.

GBR 310 is a recombinant DNA-derived humanized immunoglobulin G1 kappa monoclonal antibody and its current proposed indication is for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

In partnership with

Podcast: Strategic Insights into the RNA Market

Discover the latest trends in RNA-based therapeutics and learn how sponsors can successfully navigate the road to next generation innovation. Listen in as Citeline chats with the Director of Therapeutics at Novotech, a CRO experienced in RNA development.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.